An Upstream Strategy for Treating Severe Asthma

June 17, 2022

Thymic stromal lymphopoietin (TSLP) has been identified as starting the cascades of cytokines that result in the inflammation that underlies many cases of severe asthma. A review paper discusses how Tezspire inhibits TSLP and the evidence for its safety and efficacy in numerous clinical trials.

Dupixent Improves Severe Asthma Symptoms in a Real-World Setting, but Switching May Require Eosinophil Monitoring

May 16, 2022

Real-world study conducted in Japan shows Dupixent (dupilumab) reduced the number of annual severe asthma exacerbations by 53%. There were some reports of adverse events associated with high eosinophil levels in patients who switched to Dupixent after taking a different biologic.